Ignacio
Gil Bazo
Investigador hasta 2022
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (9)
2022
-
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations
JCO global oncology, Vol. 8, pp. e2200123
2020
-
Precision prevention and cancer interception: The new challenges of liquid biopsy
Cancer Discovery, Vol. 10, Núm. 11, pp. 1635-1644
2019
-
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
Thorax, Vol. 74, Núm. 4, pp. 371-379
-
Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network
Cancer Research, Vol. 79, Núm. 3, pp. 625-638
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899
2015
-
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546]
Biochimica et Biophysica Acta - Reviews on Cancer
2014
-
Liquid biopsies in lung cancer: The new ambrosia of researchers
Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1846, Núm. 2, pp. 539-546
-
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
Cancer Treatment Reviews, Vol. 40, Núm. 8, pp. 990-1004
2011
-
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance
Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166